Wang Austine, Bakir Noor, Ngo Clarissa, Kang Justin, Rodriguez Felipe, McKechnie Tyler, Eskicioglu Cagla, Segedi Maja, Serrano Pablo E
Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.
Division of General Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada.
Clin Transplant. 2025 Jun;39(6):e70155. doi: 10.1111/ctr.70155.
Liver transplant is indicated in patients with Wilson's disease for acute hepatic failure, advanced cirrhosis, and disease refractory to chelation therapy. This study aims to systematically review data about overall morbidity, hepatic, neuropsychiatric, and survival outcomes following liver transplantation for Wilson disease.
MEDLINE, Embase, and Central were searched from inception until July 2023. Peer-reviewed articles and published abstracts evaluating patients diagnosed with Wilson's disease and undergoing any type of liver transplant as a result of the disease were eligible for inclusion. A restricted maximum likelihood random effects model was used to generate the pooled proportion of each outcome. The risk of bias for each included observational study was assessed using the Methodological Index for Non-Randomized Studies tool.
A total of 39 studies met all inclusion criteria. All studies were observational. Specific indications for liver transplant were most commonly acute liver failure (36.73%), chronic liver failure (45.02%), and acute-on-chronic liver failure (8.35%). The pooled proportions of mortality at 30 days, 1, and 5 years were 0.10 (95% CI 0.08, 0.13; I = 16%), 0.11 (95% CI 0.09, 0.14; I = 37%), and 0.15 (95% CI 0.11, 0.20; I = 81%), respectively. The postoperative complication with the greatest prevalence was biopsy-proven acute rejection with a pooled proportion of 0.20 (95% CI 0.12, 0.31; I = 84%). The mean MINORS score for risk of bias for all studies was 8.19.
Overall, reporting quality and consistency of outcomes included in the studies was poor as assessed using the MINORS score. Pooled proportions for 30-day, 1- and 5-year mortality are similar, suggesting most postoperative deaths are acute in nature. Future research should incorporate objective measures and the reporting of standardized parameters to allow more robust comparisons between studies.
对于患有威尔逊病且出现急性肝衰竭、晚期肝硬化以及螯合疗法难治性疾病的患者,需进行肝移植。本研究旨在系统回顾威尔逊病肝移植后总体发病率、肝脏、神经精神方面以及生存结局的数据。
检索MEDLINE、Embase和CENTRAL数据库,检索时间从建库至2023年7月。经同行评审的文章以及已发表的摘要,若评估了被诊断为威尔逊病并因该病接受任何类型肝移植的患者,则符合纳入标准。使用受限最大似然随机效应模型生成各结局的合并比例。使用非随机研究方法学指数工具评估每项纳入观察性研究的偏倚风险。
共有39项研究符合所有纳入标准。所有研究均为观察性研究。肝移植的具体指征最常见的是急性肝衰竭(36.73%)、慢性肝衰竭(45.02%)以及慢加急性肝衰竭(8.35%)。30天、1年和5年时的合并死亡率分别为0.10(95%CI 0.08,0.13;I² = 16%)、0.11(95%CI 0.09,0.14;I² = 37%)和0.15(95%CI 0.11,0.20;I² = 81%)。患病率最高的术后并发症是经活检证实的急性排斥反应,合并比例为0.20(95%CI 0.12,0.31;I² = 84%)。所有研究的平均MINORS偏倚风险评分为8.19。
总体而言,使用MINORS评分评估,研究中纳入的报告质量和结局一致性较差。30天、1年和5年死亡率的合并比例相似,表明大多数术后死亡本质上是急性的。未来的研究应纳入客观测量方法并报告标准化参数,以便在研究之间进行更有力的比较。